Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 16/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 15/20 | 0.48 |
| ▸ | PDCD1 | Q15116 | 15/20 | 0.48 |
| ▸ | ATRIP | Q8WXE1 | 15/20 | 0.48 |
| ▸ | CD274 | Q9NZQ7 | 15/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.48 |
| ▸ | MTOR | P42345 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22116376 | 1.00 | ATR (0.48) | ATRCHEK1PDCD1ATRIPCD274 | |
| SCHEMBL22163219 | 0.81 | PIK3CA (0.52) | ATRCHEK1PDCD1ATRIPCD274 | |
| SCHEMBL247192 | 0.81 | PIK3CA (0.52) | ATRCHEK1PDCD1ATRIPCD274 | |
| SCHEMBL22163221 | 0.81 | PIK3CA (0.52) | ATRCHEK1PDCD1ATRIPCD274 | |
| SCHEMBL22116296 | 0.78 | ATR (0.44) | ATRCHEK1PDCD1ATRIPCD274 | |
| SCHEMBL25275495 | 0.78 | PIK3CD (0.58) | ATRCHEK1PDCD1ATRIPCD274 | |
| SCHEMBL22578850 | 0.78 | PIK3CD (0.52) | ATRCHEK1PDCD1ATRIPCD274 | |
| SCHEMBL21262049 | 0.78 | PIK3CD (0.52) | ATRCHEK1PDCD1ATRIPCD274 | |
| SCHEMBL2127456 | 0.72 | ATR (0.55) | ATRCHEK1PDCD1ATRIPCD274 | |
| SCHEMBL28539899 | 0.72 | ATR (0.55) | ATRCHEK1PDCD1ATRIPCD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3897832-B1 | N-(PYRIDIN-2-YLSULFONYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF A CFTR MEDIATED DISEASE | NOVARTIS AG (CH) | 2023-10-11 | — | — | EP | disclosed |
| US-20220033407-A1 | N-(pyridin-2-ylsulfonyl)cyclopropanecarboxamide Derivatives and their Use in the Treatment of Disease | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. | 2022-02-03 | — | — | US | disclosed |
| EP-3897832-A1 | N-(PYRIDIN-2-YLSULFONYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF A CFTR MEDIATED DISEASE | Novartis AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| CN-113226464-A | N- (pyridin-2-ylsulfonyl) cyclopropanecarboxamide derivatives and their use in the treatment of CFTR mediated diseases | 诺华股份有限公司 | 2021-08-06 | — | — | CN | disclosed |
| WO-2020128768-A1 | N-(PYRIDIN-2-YLSULFONYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF A CFTR MEDIATED DISEASE | NOVARTIS AG (CH) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033407-A1 | N-(pyridin-2-ylsulfonyl)cyclopropanecarboxamide Derivatives and their Use in the Treatment of Disease | CFTR, PKD2, PKD1 | ATR 4746/4885CHEK1 4589/4885PDCD1 4404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.